Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Cephalon Plans $161M Purchase Of Australian Company SIRTeX

Feb. 13, 2003

By Aaron Lorenzo

Aradigm Raises $15M Through Private Placement Of Shares

Feb. 13, 2003

By Aaron Lorenzo

Accelrys, Confirmant Working To Produce Protein Database

Feb. 12, 2003

By Aaron Lorenzo

Johnson & Johnson Buying Scios For $2.4 Billion In Cash

Feb. 11, 2003

By Aaron Lorenzo

It's official. Scios Inc. is selling out to Johnson & Johnson in a $2.4 billion cash deal. (BioWorld Today)

Johnson & Johnson Buying Scios For $2.4 Billion In Cash

Feb. 11, 2003

By Aaron Lorenzo

It's official. Scios Inc. is selling out to Johnson & Johnson in a $2.4 billion cash deal. (BioWorld Today)

Scios Speculated To Be Subject Of $2 Billion Acquisition By J&J

Feb. 10, 2003

By Aaron Lorenzo

Scios Inc. saw its stock price surge 21.7 percent Friday on reports that it was engaged in merger talks with Johnson & Johnson - a rumored $2 billion purchase. (BioWorld Today)

IntraBiotics Pinning Hopes On Phase II/III Study Of Iseganan

Feb. 10, 2003

By Aaron Lorenzo

Scios Speculated To Be Subject Of $2 Billion Acquisition By J&J

Feb. 10, 2003

By Aaron Lorenzo

Scios Inc. saw its stock price surge 21.7 percent Friday on reports that it was engaged in merger talks with Johnson & Johnson - a rumored $2 billion purchase. (BioWorld Today)

IntraBiotics Pinning Hopes On Phase II/III Study Of Iseganan

Feb. 10, 2003

By Aaron Lorenzo

Icogen's Chemokine Research Receives $1M SBIR Award

Feb. 6, 2003

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...